<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622047</url>
  </required_header>
  <id_info>
    <org_study_id>International Peace Xuhui</org_study_id>
    <nct_id>NCT03622047</nct_id>
  </id_info>
  <brief_title>Comparison of Epidural Labor Analgesia With Dexmedetomidine or Sufentanil</brief_title>
  <official_title>Comparison of Epidural Labor Analgesia With Dexmedetomidine or Sufentanil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Women and children’s hospital of Jiaxing university</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai First Maternity and Infant Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The participants: 1800 full-term primiparas will be selected with ASA I-Ⅱgrade, 20 to 35
      years old and weighing 55 to 90 kg in the investigator's hospital from may 2018 to December
      2018. 1200 primiparas were divided into A and B according to the computer randomized numbers,
      and 600 parturients without labor analgesia in the same period were selected as group C, with
      600 patients in each group. All parturients signed the informed consent form and were
      approved by the hospital ethics Committee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1200 primiparas were divided into A and B according to the computer randomized numbers, and
      600 parturients without labor analgesia in the same period were selected as group C, with 600
      patients in each group. All parturients signed the informed consent form and were approved by
      the hospital ethics Committee.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The onset time</measure>
    <time_frame>30 minutes</time_frame>
    <description>A drug's effects to come to prominence upon administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>analgesic effect</measure>
    <time_frame>1 day</time_frame>
    <description>VAS Score Visual analogue scale (VAS) of pain before and after analgesia</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Pharmacological Action</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Observing 0.5 μ g / ml dexmedetomidine + 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sufentanil ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>compare the analgesic effects of dexmedetomidine or sufentanil combined with ropivacaine in epidural labor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No analgesia labor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Observing with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine ropivacaine</intervention_name>
    <description>Observing the effect of 0.5 μ g / ml sufentanil+ 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.</description>
    <arm_group_label>No analgesia labor</arm_group_label>
    <arm_group_label>dexmedetomidine ropivacaine</arm_group_label>
    <arm_group_label>sufentanil ropivacaine</arm_group_label>
    <other_name>sufentanil ropivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No analgesia labor</intervention_name>
    <description>No analgesia labor control group</description>
    <arm_group_label>No analgesia labor</arm_group_label>
    <arm_group_label>dexmedetomidine ropivacaine</arm_group_label>
    <arm_group_label>sufentanil ropivacaine</arm_group_label>
    <other_name>No analgesia labor control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-Ⅱ, aged 22 - 42,

          -  gestational age ≥ 37, weight 55 - 90 kg,

          -  labor analgesia is required by full-term primiparas.

        Exclusion Criteria:

          -  serious cardiovascular and cerebrovascular system diseases,

          -  bradycardia, conduction block

          -  fetal distress

          -  contraindications of intraspinal anesthesia.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongtao Gao, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zeyong yang, MD, PhD</last_name>
    <phone>86-21-64070434</phone>
    <email>zeyongy2018@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiong Meng, MD</last_name>
    <phone>86-21-64075389</phone>
    <email>yankylge@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>International Peace Maternity and Child Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongtao Gao, MD</last_name>
      <phone>86-21-64075389</phone>
      <email>yankylge@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>zeyong yang, MD</last_name>
      <phone>86-21-64070434</phone>
      <email>zeyongy2018@aliyun.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zeyong Yang</investigator_full_name>
    <investigator_title>Department of Anesthesiology, Principal Investigator, Clinical Professor,International Peace Maternity and Child Hospital</investigator_title>
  </responsible_party>
  <keyword>Labor, Analgesia, Dexmedetomidine, Sufentanil</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

